Publications

We work hard to attract, retain, and support the most outstanding faculty.

Filter by

The New England journal of medicine

Clinical problem-solving. A red flag.

2009

Authors: Fazel R, Dhaliwal G, Saint S, Nallamothu BK

Forensic science international

Cadaveric volatile organic compounds released by decaying pig carcasses (Sus domesticus L.) in different biotopes.

2009

Authors: Dekeirsschieter J, Verheggen FJ, Gohy M, Hubrecht F, Bourguignon L, Lognay G, Haubruge E

Journal of vascular surgery

Systemic inflammation, coagulopathy, and acute renal insufficiency following endovascular thoracoabdominal aortic aneurysm repair.

2009

Authors: Chang CK, Chuter TA, Niemann CU, Shlipak MG, Cohen MJ, Reilly LM, Hiramoto JS

American journal of kidney diseases : the official journal of the National Kidney Foundation

C-reactive protein, statins, and cardiovascular risk: what can JUPITER teach us?

2009

Authors: Rogers AM, Shlipak MG

Journal of hospital medicine

The tip of the iceberg.

2009

Authors: Lieu C, Janssen WJ, Saint S, Dhaliwal G

Clinical and experimental rheumatology

Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients.

2009

Authors: Schmajuk G, Bush TM, Burkham J, Krishnan E, Chung L

Current opinion in nephrology and hypertension

Some methodological issues in studying the long-term renal sequelae of acute kidney injury.

2009

Authors: Liu KD, Lo L, Hsu CY

Menopause (New York, N.Y.) | Volume 16 of Issue 3

MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.

2009

Authors: Grady D, Sawaya GF, Johnson KC, Koltun W, Hess R, Vittinghoff E, Kristof M, Tagliaferri M, Cohen I, Ensrud KE

OBJECTIVE

To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes.

METHODS

A randomized, blinded trial in 217 postmenopausal women with hot flushes randomized to 5 or 10 g/day of MF101 or placebo for 12 weeks.

RESULTS

The effects of 5 g/day of MF101 did not differ from those of placebo. After 12 weeks, the mean percent decrease in frequency of hot flushes in the 10 g/day group was 12.9% greater than that in the placebo group (P = 0.15), the median percent decrease was 11.7% greater than that in the placebo group (P = 0.05), and the proportion of women with at least a 50% reduction in hot flushes was 16.2% greater than that in the placebo group (P = 0.03).

CONCLUSIONS

Treatment with 10 g/day of MF101 reduces the frequency of hot flushes. Trials with higher doses are planned.

HIV therapy

Mechanisms of HIV-related dyslipidemia.

2009

Authors: Julie Womack,Phyllis C Tien

Journal of general internal medicine | Volume 24 of Issue 5

Fact or fiction: the need for independent pharmaceutical policy research.

2009

Authors: Keyhani S, Federman A